Incyte (YTE) Appoints Dr. Issa as EVP, Strengthening Oncology Leadership and Innovation

Incyte Strengthens Leadership with New Executive Appointment

Incyte Corporation, a leading biopharmaceutical company headquartered in Wilmington, Delaware, enhances its executive team with the appointment of Dr. Mohamed Issa as Executive Vice President and Head of U.S. Oncology. This strategic move is pivotal for Incyte as it aims to solidify its position in the oncology sector, particularly through innovative therapeutics that address significant unmet medical needs. Dr. Issa, who brings extensive experience in oncology, will play a crucial role in driving the development and commercialization of the company’s oncology portfolio, which includes several first-in-class medicines.

To support Dr. Issa's transition into the company, Incyte grants him a substantial equity inducement award consisting of 48,671 restricted stock units (RSUs). The vesting of these units begins on January 6, 2025, with a structured increment of 25% vesting on each anniversary over the next four years. This award not only signifies Incyte's commitment to attracting top talent but also aligns Dr. Issa’s interests with the long-term success of the company. Incyte's decision to offer such inducements underscores its focus on building a resilient leadership team that can navigate the complex landscape of oncology therapeutics.

In addition to Dr. Issa's appointment, Incyte also awards 9,502 RSUs to 14 new employees under its 2024 Inducement Stock Incentive Plan. These RSUs, set to commence vesting on January 2, 2025, are designed to incentivize new talent in alignment with Nasdaq Listing Rule 5635(c)(4). With this initiative, Incyte not only strengthens its workforce but also reinforces its commitment to innovation in the biopharmaceutical sector, particularly in addressing critical health issues through its diverse pipeline that spans Oncology, Inflammation, and Autoimmunity.

Incyte remains dedicated to discovering and developing innovative therapeutics that can significantly improve patient outcomes. Its commitment to scientific excellence is evident in its expansive operations across North America, Europe, and Asia, ensuring that the company is well-positioned to respond to the evolving needs of global healthcare. By fostering talent and enhancing its leadership capabilities, Incyte is poised to make substantial advancements in the biopharmaceutical industry.